AU2011341337A1 - Dosage and administration of bispecific scFv conjugates - Google Patents

Dosage and administration of bispecific scFv conjugates Download PDF

Info

Publication number
AU2011341337A1
AU2011341337A1 AU2011341337A AU2011341337A AU2011341337A1 AU 2011341337 A1 AU2011341337 A1 AU 2011341337A1 AU 2011341337 A AU2011341337 A AU 2011341337A AU 2011341337 A AU2011341337 A AU 2011341337A AU 2011341337 A1 AU2011341337 A1 AU 2011341337A1
Authority
AU
Australia
Prior art keywords
dose
composition
intervals
days
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011341337A
Other languages
English (en)
Inventor
Francis Gibbons
Charlotte Mcdonagh
Victor Moyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of AU2011341337A1 publication Critical patent/AU2011341337A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2011341337A 2010-12-10 2011-12-12 Dosage and administration of bispecific scFv conjugates Abandoned AU2011341337A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42199210P 2010-12-10 2010-12-10
US61/421,992 2010-12-10
PCT/US2011/064496 WO2012079093A2 (en) 2010-12-10 2011-12-12 Dosage and administration of bispecific scfv conjugates

Publications (1)

Publication Number Publication Date
AU2011341337A1 true AU2011341337A1 (en) 2013-06-13

Family

ID=46207797

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011341337A Abandoned AU2011341337A1 (en) 2010-12-10 2011-12-12 Dosage and administration of bispecific scFv conjugates

Country Status (6)

Country Link
US (1) US20140017264A1 (https=)
EP (1) EP2648753A4 (https=)
JP (1) JP2014500278A (https=)
AU (1) AU2011341337A1 (https=)
CA (1) CA2819554A1 (https=)
WO (1) WO2012079093A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
CN103547598A (zh) * 2011-02-24 2014-01-29 梅里麦克制药股份有限公司 包含抗-erbb3药剂的联合治疗
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
MX2014013763A (es) * 2012-05-11 2015-02-20 Merrimack Pharmaceuticals Inc Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer.
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2016022723A1 (en) 2014-08-05 2016-02-11 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
MX2010011145A (es) * 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.

Also Published As

Publication number Publication date
WO2012079093A2 (en) 2012-06-14
EP2648753A2 (en) 2013-10-16
EP2648753A4 (en) 2015-06-24
US20140017264A1 (en) 2014-01-16
CA2819554A1 (en) 2012-06-14
JP2014500278A (ja) 2014-01-09
WO2012079093A3 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
US20140017264A1 (en) Dosage and administration of bispecific scfv conjugates
US7794713B2 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP2004527456A (ja) Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
CN104487088A (zh) 治疗gd2阳性癌的方法
EP3042669A1 (en) Antitumor agent and antitumor effect enhancer
US12383620B2 (en) Phthalocyanine dye conjugate compositions
JP6488273B2 (ja) 前立腺癌治療のための抗アルファ−ｖインテグリン抗体
CN118806923A (zh) 西妥昔单抗-ir700偶联物组合物
RU2011146339A (ru) Комбинированная терапия с использованием агента (ов) против igfr и специфических ингибиторов igf-1r
EP4025603A1 (en) Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
AU2005325227B2 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2019238713A2 (en) Treatments etc
US20200093789A1 (en) Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor
CN119255817A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
US20250381268A1 (en) Pharmaceutical composition comprising anti-ctla4 and anti-pd1 antibody mixture and therapeutic use thereof
WO2023160517A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
CN118946366A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
KR20210106197A (ko) EGFR과 Her2 발현 암세포를 타겟으로 하는 항체-약물 중합체 개발
CN119300862A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2025238587A1 (en) Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
KR20260042531A (ko) Pcsk9 억제제를 이용하여 콜레스테롤 관련 질환을 치료 또는 예방하기 위한 방법

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period